Merck Return on Tangible Equity 2010-2022 | MRK

Current and historical return on tangible equity values for Merck (MRK) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Merck Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-06-30 $16.58B $-0.39B -1097.58%
2022-03-31 $14.18B $-3.33B -1192.35%
2021-12-31 $13.05B $-5.94B -579.70%
2021-09-30 $7.20B $3.62B -270.45%
2021-06-30 $5.57B $0.89B -101.67%
2021-03-31 $7.03B $-7.57B -88.68%
2020-12-31 $7.07B $-7.58B -83.92%
2020-09-30 $11.52B $-7.66B -136.61%
2020-06-30 $10.48B $-8.89B -135.50%
2020-03-31 $10.15B $-9.56B -149.34%
2019-12-31 $9.84B $-7.62B -205.97%
2019-09-30 $9.31B $-4.86B -233.26%
2019-06-30 $9.36B $-5.13B -421.47%
2019-03-31 $8.40B $-1.50B -1557.53%
2018-12-31 $6.22B $-4.48B 1728.98%
2018-09-30 $3.35B $2.22B 166.97%
2018-06-30 $1.34B $1.59B 49.57%
2018-03-31 $1.58B $2.10B 43.69%
2017-12-31 $2.39B $2.10B 55.59%
2017-09-30 $2.85B $5.02B 57.04%
2017-06-30 $5.09B $5.24B 101.06%
2017-03-31 $4.35B $4.87B 85.97%
2016-12-31 $3.92B $4.84B 77.98%
2016-09-30 $5.49B $5.19B 111.43%
2016-06-30 $5.13B $5.32B 109.71%
2016-03-31 $4.61B $4.75B 105.04%
2015-12-31 $4.44B $4.44B 105.05%
2015-09-30 $10.78B $4.19B 154.66%
2015-06-30 $9.85B $4.18B 111.04%
2015-03-31 $11.17B $4.10B 90.79%
2014-12-31 $11.92B $15.41B 73.32%
2014-09-30 $5.39B $11.79B 32.71%
2014-06-30 $5.61B $17.90B 33.55%
2014-03-31 $4.52B $19.93B 29.80%
2013-12-31 $4.40B $16.22B 31.47%
2013-09-30 $4.53B $12.88B 33.57%
2013-06-30 $5.14B $11.57B 36.15%
2013-03-31 $6.02B $15.29B 40.72%
2012-12-31 $6.17B $14.25B 44.02%
2012-09-30 $6.76B $15.72B 51.76%
2012-06-30 $6.72B $13.90B 58.34%
2012-03-31 $6.95B $12.16B 68.36%
2011-12-31 $6.26B $10.49B 71.04%
2011-09-30 $4.22B $9.55B 56.77%
2011-06-30 $2.87B $8.48B 50.40%
2011-03-31 $1.60B $6.73B 38.93%
2010-12-31 $0.86B $4.97B 28.06%
2010-09-30 $7.84B $2.61B 349.84%
2010-06-30 $10.92B $2.16B 147.07%
2010-03-31 $11.73B $2.50B 97.18%
2009-12-31 $12.85B $1.69B 78.24%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.318B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17